BrainTale has been developing non-invasive, accessible, effective and clinically validated measurement and prediction tools for patients suffering from brain diseases BrainTale, a medtech deciphering white matter to enable better brain care, presented preliminary results demonstrating the effectiveness of its digital biomarker platform for the early and differential diagnosis of Parkinson’s disease. Results were presented during…
Buntanetap in PD faces challenges despite phase III progress
Annovis Bio recently received a positive safety review for the Phase III trial of buntanetap in patients with early Parkinson’s Disease (PD) (NCT05357989) from the Data and Safety Monitoring Board (DSMB). Should buntanetap demonstrate good efficacy and safety profiles in the trial, it could be the first α-synuclein-targeting product to enter the market and one…
Concussion guidance for teachers and parents
N-ABLES produces ‘Return-to-School’ concussion guide Easy-to-use, concise guidance for the return-to-school (RTS) following concussion has been produced by UKABIF National Acquired Brain Injury Learning and Education Syndicate (N-ABLES). This two-page document entitled ‘Concussion Return-to-School Guidance’ reiterates the staged return-to-education advocated in the Government’s new grassroots sports guidance but is aimed directly at teachers and parents…
Magstim Horizon 3.0 Transcranial Magnetic Stimulation now in UK
Approval by UKCA Empowers UK physicians to advance care of Treatment Resistant Depression, Obsessive Compulsive Disorder, and Anxious Depression with non-invasive brain stimulation The advanced and FDA-cleared Magstim Horizon 3.0 transcranial magnetic stimulation (TMS) system is now UKCA registered and available for sale in the UK, providing physicians with a proven precision therapy to improve…
FDA approves LEQEMBI™ (lecanemab-irmb)
Traditional approval for the treatment of Alzheimer’s disease in the US July 6, 2023: Eisai Co Ltd and Biogen Inc have announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, making LEQEMBI the first and…
Real-world study on AJOVY® reveals sustained long-term effectiveness in migraine
Data presented at the European Academy of Neurology Congress 2023: Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine JULY 2023, TEL AVIV, Israel: Teva Pharmaceutical Industries Ltd has announced further positive data from…
AI in stroke: tool outperforms human emergency call handlers in identifying stroke
AI in stroke: A team of researchers from Denmark have developed a new artificial intelligence (AI) framework to address the number of strokes that go unrecognised by human emergency call handlers.[i] The framework outperformed emergency call handlers in recognising stroke for both sexes and across all age groups studied, indicating its potential as a supplementary…
Could new materials lead to implantable treatments for epilepsy?
Breakthrough research on materials may help new types of probes be safely implanted in the brain. Bioengineering researchers from the University of Glasgow have investigated new dissolvable coatings which could help safely guide flexible implants into brains to help regulate temporal lobe epilepsy. The development of the material, outlined in an early-view paper in the…
Opicapone 50mg in adult levodopa treated PD patients without motor complications
BIAL announces positive results from phase 3 study June 5th, 2023: BIAL announces positive topline results of its phase 3 EPSILON (Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe) study evaluating opicapone 50mg in adult levodopa treated Parkinson’s Disease (PD) patients without motor complications. In the EPSILON study, opicapone 50 mg was found to be statistically significantly…
